ClinicalTrials.gg
CompletedNCT00091572Updated Jun 6, 2017Results posted

Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)

A Phase 3 interventional study of Temozolomide and Dacarbazine in Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
859
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing temozolomide in Melanoma — 2 open to participants now, 2 under way, none of them phase 3. Temozolomide · Melanoma.

Enrollment
Largest of 46
859 · median 28
Started
2004
with 3 others
Phase 3
3 of 50
none open now
Registered
10th of 50
by date
Lead sponsor
2 of 50
Merck Sharp & Dohme LLC

Among the 50 studies testing temozolomide in Melanoma, this one has the largest enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2004, is one of 3 in phase 3, and was the 10th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 50 studies testing temozolomide in Melanoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing temozolomide in Melanoma, or all of them as a file.
02

Study summary

The purpose of this study is to ascertain if the extended schedule of Temozolomide, which allows increased doses and potential depletion of the enzyme underlaying resistance, is a more effective treatment of metastatic melanoma than single agent dacarbazine.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Metastatic Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, stage IV, surgically incurable melanoma
  • Age 18 years or older
  • World Health Organization (WHO) (ECOG) performance status of 0 or 1
  • Meets protocol requirements for specified laboratory values
  • Must be able to take oral medication
  • Must be disease free from cancer for period of 5 years (except for surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin).
  • Women of and men must be practicing a medically approved .
  • Must provide written informed-consent to participate in the study.
  • Must have full recovery from major surgery or treatment
  • No clinically uncontrolled infectious disease including or AIDS-related illness

Exclusion criteria

Exclusion Criteria:

  • Ocular melanomas
  • Prior cytokine or chemotherapy for stage IV disease
  • Pregnant or nursing women
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
859 participants (actual)

Study arms

  • Experimental
    A

    temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days ("7 days on / 7 days off" continuously)

    Drug: Temozolomide

  • Active comparator
    B

    dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks

    Drug: Dacarbazine

Interventions

  • oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days ("7 days on / 7 days off" continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.

    Also known as: Temodal, Temodar, SCH 52365

  • intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.

    Also known as: DTIC-Dome

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall Survival was defined as the time from the date of randomization to the date of death from any cause.

    Time frame: The final analysis was to be performed when at least 616 deaths had occurred.

Secondary outcomes

  1. Progression Free Survival

    Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause.

    Time frame: Treatment continued until disease progression or unacceptable toxicity. Patients will be followed for survival.

  2. Objective Response Rate in Subjects With Measurable Lesions

    Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter.

    Time frame: Treatment continued until disease progression or unacceptable toxicity.

  3. Duration of Objective Response

    Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented.

    Time frame: Treatment continued until disease progression or unacceptable toxicity.

07

Results

Posted Mar 12, 2009

Participant flow

Participant flow — Overall Study
MilestoneTemozolomideDacarbazine
Started429430
Completed334348
Not completed9582
Withdrew: Lost to follow-up11
Withdrew: Subject's refusal unrelated to toxicity1422
Withdrew: Death not due to malignancy/toxicity13
Withdrew: Medical decision unrelated toxicity/pd1022
Withdrew: Other reason613
Withdrew: Ongoing (still on treatment)812
Withdrew: Major protocol violation20
Withdrew: Toxicity (related ae)539

Outcome measures

SecondaryProgression Free Survival

Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause.

Time frame:
Treatment continued until disease progression or unacceptable toxicity. Patients will be followed for survival.
Reported as:
Median · Months
Progression Free Survival
MonthsTemozolomideDacarbazine
Progression Free Survival2.30 (2.23 to 2.43)2.17 (2.14 to 2.27)
Statistical analysis
  • Temozolomide vs Dacarbazine · Log Rank · p = 0.2663 · Hazard ratio (hr): 0.92 · 95% CI 0.80 to 1.06Temozolomide events (progressions/deaths) = 401. Dacarbazine events (progressions/deaths) = 398.
PrimaryOverall Survival

Overall Survival was defined as the time from the date of randomization to the date of death from any cause.

Time frame:
The final analysis was to be performed when at least 616 deaths had occurred.
Reported as:
Median · Months
Overall Survival
MonthsTemozolomideDacarbazine
Overall Survival9.13 (8.11 to 9.89)9.36 (8.21 to 10.28)
Statistical analysis
  • Temozolomide vs Dacarbazine · Log Rank · p = 0.9999 · Hazard ratio (hr): 1.00 · 95% CI 0.86 to 1.17Temozolomide events (deaths) = 320. Dacarbazine events (deaths) = 325.
SecondaryObjective Response Rate in Subjects With Measurable Lesions

Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter.

Time frame:
Treatment continued until disease progression or unacceptable toxicity.
Reported as:
Median · Ratio
Objective Response Rate in Subjects With Measurable Lesions
RatioTemozolomideDacarbazine
Objective Response Rate in Subjects With Measurable Lesions0.14 (0.10 to 0.17)0.10 (0.07 to 0.12)
Statistical analysis
  • Temozolomide vs Dacarbazine · Cochran-Mantel-Haenszel · p = 0.0718 · Odds ratio (or): 1.43 · 95% CI 0.97 to 2.12Temozolomide numerator (responders) = 55. Dacarbazine numerator (responders) = 37.
SecondaryDuration of Objective Response

Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented.

Time frame:
Treatment continued until disease progression or unacceptable toxicity.
Reported as:
Median · Months
Duration of Objective Response
MonthsTemozolomideDacarbazine
Duration of Objective Response4.34 (4.17 to 6.18)8.31 (6.08 to 19.25)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Temozolomide—124/419 (29.6%)394/419 (94%)
Dacarbazine—100/421 (23.8%)374/421 (88.8%)
Most frequent serious events
Showing 10 of 163
Most frequent serious events
EventTemozolomideDacarbazine
PLATELET COUNT DECREASEDInvestigations21/4193/421
VOMITINGGastrointestinal disorders15/4199/421
NAUSEAGastrointestinal disorders11/41910/421
NEUTROPHIL COUNT DECREASEDInvestigations9/4193/421
ABDOMINAL PAINGastrointestinal disorders6/4198/421
PYREXIAGeneral disorders3/4198/421
FATIGUEGeneral disorders7/4195/421
DYSPNOEARespiratory, thoracic and mediastinal disorders7/4194/421
HAEMOGLOBIN DECREASEDInvestigations3/4197/421
CONSTIPATIONGastrointestinal disorders6/4192/421
Most frequent other events
Showing 10 of 27
Most frequent other events
EventTemozolomideDacarbazine
NAUSEAGastrointestinal disorders286/419206/421
FATIGUEGeneral disorders253/419240/421
VOMITINGGastrointestinal disorders211/419103/421
CONSTIPATIONGastrointestinal disorders183/419111/421
ANOREXIAMetabolism and nutrition disorders118/41979/421
HEADACHENervous system disorders92/41956/421
WEIGHT DECREASEDInvestigations87/41945/421
DIARRHOEAGastrointestinal disorders79/41971/421
PRURITUSSkin and subcutaneous tissue disorders75/41929/421
COUGHRespiratory, thoracic and mediastinal disorders71/41951/421

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TemozolomideDacarbazineTotal
<=18 years000
Between 18 and 65 years276261537
>=65 years153169322
Sex: Female, Male
Sex: Female, Male(Participants)TemozolomideDacarbazineTotal
Female179177356
Male250253503
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A; EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011 Jul;47(10):1476-83. doi: 10.1016/j.ejca.2011.04.030. Epub 2011 May 18. PubMed 21600759 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2004 to primary completion in Dec 2007, 38 months.

Results were first posted in Mar 2009, 1 year 2 months after primary completion.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 38 months is close to that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2004
First posted
Sep 14, 2004
StartActual
Oct 20, 2004
Primary completionActual
Dec 31, 2007
CompletionActual
Dec 31, 2007
Results first posted
Mar 12, 2009
Last update
Jun 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00091572
Responsible party
Sponsor
First posted
Sep 14, 2004
Start date
Oct 20, 2004
Primary completion
Dec 31, 2007
Completion
Dec 31, 2007
Results posted
Mar 12, 2009
Last update
Jun 6, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion